Background - Researchers have for several
decades been concerned that the prolonged production of adrenal stress hormones
- the glucocorticoids – could damage the brain and disrupt immune
and sympathetic nervous system functioning. This paradigm of stress related
disease has been almost entirely focused on increased not decreased cortisol
production. Multiple studies have indicated that major depression is associated
with high cortisol levels.
Studies in the last ten years or so, however, have indicated that a different
kind of stress disorder – one characterized not by over but by under activity of
the HPA axis – may be of equal concern. Hypocortisolism has been found in CFS,
FMS, chronic pelvic pain syndrome, post traumatic stress syndrome (PTSD),
rheumatoid arthritis (RA), asthma and allergies. Studies finding that people
with these diseases report higher than normal rates of major stressors prior to
their becoming ill have suggested an altered stress response may be implicated
in their illness. Several researchers now posit that hypocortisolism may
underlie the pathology in a wide range of diseases characterized by increased
autoimmunity, inflammation, pain, fatigue, asthma or allergies. A 1994 study
indicated that patients with genetically derived resistance to glucocorticoids
often developed symptoms similar to those found in CFS and FMS.
Glucocorticoid resistance or the impaired responsiveness to glucocorticoids do
not appear to be the same as hypocortisolism but can for the purposes of this paper be
considered synonymous with it; both result in impaired glucocorticoid activity.
While hypocortisolism has been linked with increased stress it is not,
however,
necessarily tied to disease. At least five studies have found hypocortisolism in
healthy individuals who were under chronic stress.
Setting the Stage - Producing Cortisol -
How is cortisol produced? The cortisol production pathway is given below
- a physical or psychological stressor prompts the release of corticocotropin releasing
hormone (CRH) from the hypothalamus
- CRH and arginine vasopressin trigger the production of adrenocorticotropic
hormone (ACTH) from the pituitary.
- ACTH causes the adrenal glands to release cortisol
- To Review - CRH (hypothalamus) + ACTH (pituitary) = cortisol (adrenal glands).
Hypocortisolism and CFS: the Evidence
With 23 studies on it and
counting cortisol is certainly the most well studied
substance in CFS. The evidence for hypocortisolism in CFS is, however,
hardly overwhelming. Of the 23 studies done since 1991 that have measured
urinary, salivary or plasma cortisol levels only just over 50% (n=12) have found
low cortisol levels. The evidence for low ACTH - the second stage in the
cortisol production pathway - is even poorer; only 3/8 studies
found low ACTH levels in CFS.
Basal cortisol and ACTH levels only tell part of the story, however. A
more important question concerns how well the pituitary (ACTH) and adrenal
glands (cortisol) respond to stress. CFS patients could have normal resting
hormone levels and still have low hormone levels under stress; an underactive
stress response could then cause them problems in dealing with stressors such as
exercise, psychological stress, infection, etc.
The evidence for a hypoactive stress response in CFS is fairly strong; 2/3rds of studies
(8/12) have found a reduced ACTH response to stress. Since, as noted above, ACTH production by
the pituitary triggers cortisol production by the adrenal glands, a reduced ACTH
response could result in reduced cortisol production during the stress of
infection, exercise, etc. Of the five studies that examined the cortisol
response to stress, however, only two, found an impaired cortisol response.
Producing a Hypercortisolic State –
What could cause a hypocortisolic state in CFS? Raison and Miller state there are at least six ways to reduce the effectiveness
of glucocorticoids in the body. Some of the them entail reducing cortisol
levels, others simply impair the effectiveness of cortisol when it is present.
Either way all result in lowered cortisol activity. They are:
- Reduced production of the hormonal triggers needed for cortisol
production (CRH/ACTH)
- A defect in adrenal gland production or release
- Defective binding proteins for cortisol that reduce cortisol
availability to the cell
- A problem in the enzymes that metabolize glucocorticoids once they are
in the cell
- A defect in the (multidrug) pump that pumps cortisol out of the cell
- Altered receptor levels or responsiveness
Is there evidence for any of these in CFS? There is some evidence for reduced
CRH/ACTH production/responsiveness in CFS. There is also evidence of reduced
adrenal gland productivity. Torpy found a trend towards increased frequency in
CFS patients of a mutation in the cortisol binding globulin gene (CBG). Since
CBG delivers cortisol to the cell then impaired CBG functioning would exacerbate
any cortisol deficiencies already present (Torpy
et. al. 2001). Torpy's study of a family with these mutations found they bore
some similarities to CFS; they were often obese, they had low systolic and
diastolic blood pressures and experienced overwhelming fatigue and moderate
joint pain. They did not, however, display any of the flu symptoms often associated with
CFS. Several family members did, however, met the CDC criteria for
CFS and one did for FMS. Overall most studies suggest the HPA axis in CFS is under-responsive to stimuli.
Exacerbating An Already Bad Situation
- Low hormone levels are usually counterbalanced by high levels of receptors
for those hormones. Several studies indicate, however, that the opposite may be
true in several diseases (chronic pelvic pain, FMS, RA and arthritis) associated with hypocortisolism One study found that exposure to
an allergen decreased the affinity cortisol receptors have for cortisol in allergy
patients. Allergy is by definition an overactive immune response and cortisol is
an important immune regulator. This study suggests that the allergic condition
impairs the ability of the endocrine system to rein the immune system in.
But how could such a paradoxical situation develop? Why would receptor
activity for cortisol fall instead of increase in the face of low cortisol
levels. Why would the body exacerbate the cortisol deficiency already present?
One intriguing answer given the immune activation sometimes seen in CFS involves
increased levels of pro-inflammatory cytokines. Several studies have shown that
increased levels of the IL-1a cytokine levels impair glucocorticoid receptor functioning. This suggests
hypocortisolism could be exacerbated by as well as exacerbate a chronic
infection. Thus the hypocortisolism in CFS could be caused by a chronic
infection or contribute to the risk of a chronic infection or both (See below).
It is not clear if this is happening in CFS but it illustrates the complex
nature of the cortisol/immune reaction -an interaction that has barely begun to
be explored in CFS.
Hypercortisolism and Immune Activation
– Infection is one of the many stressors that activate the stress
response. Cortisol’s immunosuppressive effects include reducing lymphocyte
functioning, macrophage activation, NK cell functioning, antigen presentation,
T-cell proliferation and pro-inflammatory cytokine production. Cortisol's ability
to inhibit phospholipase activity suggests reduced cortisol levels could also result
in increased prostaglandin levels which would cause increased inflammation and pain. There is also evidence
that hypocortisolism may result in reduced immune cell movement as well– a critical
process in fighting infection.
The presence of hypocortisolism in an autoimmune disease, rheumatoid
arthritis (RA), and two diseases associated with immune hyperresponsivity, asthma and
allergy, supports the conjecture that low cortisol
levels can lead to immune
activation. More studies need to be done, however, to determine how important hypocortisolism is to the development and/or exacerbation of autoimmune and
immune diseases.
Hypercortisolism is found in people with major depression. Not
surprisingly given their high cortisol levels, depressed people usually exhibit
reduced responsiveness to glucocorticoids. (As noted earlier the body commonly
compensates for high levels of a substance by reducing its quickly it responds
to it).
This reduced responsiveness extends, interestingly enough, to the immune system.
Poor glucocorticoid regulation of the immune system is believed to be
responsible for the increased levels of inflammatory markers (Il-1, Il-6, TNF-a)
often found in patients with major depression.
Raison and Miller suggest that, at least with regard to the immune system,
that the hypocortisolism seen in CFS is a mirror image to the hypercortisolism
seen in depression – both result in increased inflammation; one through reduced
responsiveness to glucocorticoids (depression), and one through reduced levels
of glucocorticoids (CFS). In either case the ability of the stress response
system to contain the immune response has been impaired. This should result
in increased levels of the main immune system mediators - the cytokines. It has
long been intriguing that many symptoms in CFS are similar to those found in
conditions with high cytokine levels. The state called ‘sickness behavior’ -
which most of us go through when we catch a cold - characterized by fever,
malaise, fatigue, poor concentration, etc., is believed to be caused by high
cytokine levels in the brain. (This 'behavioral response' is believed
triggered by the brain in order to cause the ill
patient to slow down and conserve their energy for fighting off the pathogen.)
An inability to rein in the immune system because of a hypocortisolic
state could result in increased cytokine levels and a prolonged state of
'sickness behavior' in CFS.
Not only can glucocorticoids inhibit the immune response but cytokines can,
by impairing glucocorticoid receptor number and activity, impair the
glucocorticoid response. This suggests the following feed forward mechanism
could exist in a hypocortisolic state; low cortisol levels could lead to an
inflammatory cascade that further impairs cortisol production which in turn
leads to further cytokine production, etc.
This theory predicts that the hypocortisolic
state in CFS should result in immune system activation. But are the immune systems of
CFS patients activated? Much of the evidence is mixed; pro-inflammatory cytokine
levels are sometimes increased in studies of CFS patients and sometimes not. A
more compelling argument for immune activation in CFS may come from a recent
study showing that impaired natural killer cell and T-cell activity in
CFS is probably due to immune cell ‘burn out’ from over-activation.
Further evidence of immune activation comes from the gene expression studies in
the form of increased numbers of immune genes, and increased
rates of RNase L fragmentation and allergy in CFS.
Evidence For An Impaired Cortisol/Immune Interface
in CFS - Only one study has started to
examine whether the hypercortisolic state in CFS is synonymous with immune
activation in CFS. This study found that the ability of glucocorticoids such as cortisol to
regulate immune activity was impaired in CFS. This is opposite to what was
expected; the researchers thought, given the low levels of cortisol usually
found in CFS, that the immune cells in CFS patients would have been
hyper-responsive to it; as we noted earlier the body usually
compensates for a deficiency in a substance by increasing its
responsiveness to it. The opposite appears to have happened in CFS; this would,
of course,
exacerbate the effects the low cortisol levels might have on immune regulation in CFS.
Hypocortisolism and Sympathetic Nervous System (SNS)
Activation – Since cortisol also restrains the production,
turnover and release of the catecholamines (norepinephrine/epinephrine) that
regulate SNS activity, a hypocortisolic state could lead to
increased SNS
activity. Several studies have found evidence of increased SNS activity in CFS.
Hypocortisolism - A Protective Mechanism?
Could the hypocortisolism found in CFS be protective? Dr Cheney has long
postulated the fatigue present in CFS is more a protective than pathologic
feature.
The idea that the body can produce symptoms or ‘behaviors’ during illness
that compel an individual to save their energy for healing is not new. As noted
above the
symptoms produced during the acute stages of infectious disease called ‘sickness
behavior’ such as malaise, fever, poor concentration, sleepiness are believed to
be produced by cytokines. In a similar sense the pain produced during trauma is
designed to limit the use of wounded limb.
Raison and Miller suggest that hypocortisolism could be an adaptive response
to certain types of chronic stress. We know the stress response plays a key role in ramping down the
production of pro-inflammatory cytokines during the later parts of an infection.
But what if the infection has not been resolved by the time the immune system
inhibition has occurred? Wouldn’t immune system down regulation be injurious at
that point? Raison and Miller ask which is worse - an ongoing infection or an
impaired stress response, and come down squarely on the side of an ongoing
infection. They suggest that the body could lower its production of glucocorticoids
in order to allow the immune system to ramp up again.
Several CFS researchers have suggested a process like this could be occurring
in CFS. In 2003 Van Hoof, Cluydts and De Meirleir posited that the atypical depression (fatigue, malaise,
aching muscles, etc.) often seen in CFS is not due to an affective (mental)
disorder but is an adaptive course the body has taken to
save it’s resources for battling a chronic infection. They note that the
administration of the pro-inflammatory cytokine Il-1 has been shown to produce
long term changes in HPA axis activity in laboratory animals. Similarly
depression and fatigue often follow the administration of the cytokine
interferon as well.
The idea that the hypocortisolism found in CFS is an adaptive or protective
response is interesting given a study indicating that elderly subjects with
hypocortisolism had lower levels of allostatic load than elderly subjects
with normal cortisol levels. Since aging is synonymous with stress this study
suggests that hypocortisolic state may be advantageous during periods of chronic
stress. This scenario suggests that without the hypocortisolism present in CFS,
CFS patients would have higher allostatic loads than they do.
The consequences of chronic immune activation that might result from this can be severe, however, and
include an increased risk of autoimmune diseases and increased cell death in the
central nervous system (CNS). The pro-inflammatory cytokine TNF-a released
during chronic immune activation is neurotoxic
to cells in an area of the brain (hippocampus) involved in regulating the stress
response. Rodents treated with an anti-glucocorticoid agent designed to put them
into a hypocortisolic state demonstrated increased TNF-a associated
neurodegeneration.
Conclusions – It is impossible at this
point to know how important hypocortisolism is in CFS. While it seems clear that
hypocortisolism is often present in CFS it is unclear whether it is simply a
product of the chronic stress present in CFS or if it is a central factor in CFS
pathophysiology. Some recent studies have suggested the former is more likely to
be true. A finding that reduced cortisol levels are correlated with disease
duration suggest it is a function of chronic stress that builds over time. A
prospective study that did not find altered HPA axis functioning in EBV patients
with long term fatigue suggested the same. A study that temporarily resolved the
hypocortisolic state in CFS through the use of hydrocortisone which found some
benefits but that in no way resulted in the resolution of CFS suggested that hypocortisolism
is a secondary not primary factor in CFS.
There is no denying, however, that several of the postulated effects of
hypocortisolism are found in CFS, most notable of which is immune activation.
The presence of a hyporcortisolic state in allergy, a disease of Th2 cytokine
activation and in rheumatoid arthritis, an autoimmune disease, suggests
hypocortisolism can have profound immune effects. The presence of a hypocortisolic state in FMS, a disease which has much in common with CFS, is
interesting to say the least.
While the hypercortisolic theory is intriguing much more work needs to be
done before its importance in CFS can be determined. It is difficult, indeed, for
CFS patients to accept that any disturbance ususally described as ‘mild’ could be central
in a disease that is as debilitating as CFS can be. In this light future studies that
examine factors that could further decrease cortisol availability in CFS (i.e. GR
receptor levels and affinity, cortisol binding proteins) may be important. Also
important given the cortisol/immune interactions found are studies that examine
the efficacy of this relationship in CFS patients. A greatly impaired immune
responsiveness to cortisol in CFS could transform a mild cortisol
insufficiency into something much more significant.
Prospective studies that monitor HPA axis activity as individuals come down with
CFS will also be important to resolving the role the HPA axis plays in CFS. While the hypercortisolic
theory has promise one feels it is still missing a central component in CFS.
_________________________
Heim, C., Ehlert, U. and D. Hellhammer. 2000. The
potential role of hypocortisolism in the pathophysiology of stress-related body
disorders. Psychoneuroendocrinology 25, 1-35.
Fries, E., Hesse, J., Hellhammer, J., Hellhammer, D.
2005. A new view on hypocortisolism. Psychoneuroendocrinology xx. 1-7.
Raison, C., Miller, A. 2003. When not enough is too
much: the role of insufficient glucocorticoid signaling in the pathophysiology
of stress-related disorders. Am. J. Psychiatry 160, 1554-1565.
Torpy, D., Bachman, A., Grice, J., Fitzgerald, S., Phillips, P., Whitworth,
J. and R. Jackson. 2001. The Journal of Clinical Endocrinology and Metabolism
86, 3692-3700.
Torpy, D. Bachman, A., Gartside, M., Grice, J., Harris, J., Clifton, P.,
Easteal S., Jackson R. and J. Whitworth. 2004. Association between chronic
fatigue syndrome and the corticosteroid-binding globulin gene ALA SER224
polymorphism. Endocr. Res. 30, 417-29.
Van Hoof, E., Cluydts, R., De Meirleir, K. 2003.
Atypical depression as a secondary symptom in chronic fatigue syndrome. Medical
Hypotheses 61, 52-55